Q2017 HCPCS Level II code: Injection, teniposide, 50 mg
CMS terminated Q2017: its last date of service was Dec 31, 2025. It stays here for looking up older claims; newer services need a current code.
Official description
Q2017Injection, teniposide, 50 mg
Short description: Teniposide, 50 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with Q2017 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Coverage statute
- 1861S2B
- Added
- Jul 1, 2000
- Terminated after
- Dec 31, 2025
Where Q2017 sits
- 1Q codesTemporary codes
- 2Terminated Q2017Injection, teniposide, 50 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q2017 still valid?
No. CMS terminated Q2017; its last date of service was Dec 31, 2025. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q2017?
CMS lists Q2017’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q2017
All Q codesQ0520Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-daysQ0521Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescriptionQ1004New technology intraocular lens category 4 as defined in federal register noticeQ1005New technology intraocular lens category 5 as defined in federal register noticeQ2004Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 mlQ2009Injection, fosphenytoin, 50 mg phenytoin equivalentQ2026Injection, radiesse, 0.1 mlQ2028Injection, sculptra, 0.5 mgQ2034Influenza virus vaccine, split virus, for intramuscular use (agriflu)Q2035Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)Q2036Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)Q2037Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)